New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Editas Medicine, Inc. (EDIT) vs Lexeo Therapeutics, Inc. (LXEO)

Editas Medicine, Inc. and Lexeo Therapeutics, Inc. are both Biotechnology companies. Editas Medicine, Inc. and Lexeo Therapeutics, Inc. are of similar size ($267.4M and $263.9M). Across the 10 metrics below, Editas Medicine, Inc. leads on 5 and Lexeo Therapeutics, Inc. on 5.

Valuation

Metric EDIT LXEO Biotechnology median
P/E n/m n/m 8.49
P/S 5.02 — 8.56
P/B 2.96 1.22 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 1.21 — 8.00
Earnings yield (38.18%) (42.15%) (35.81%)
Free cash flow yield (44.01%) (33.31%) (25.41%)

Profitability

Metric EDIT LXEO Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (151.71%) — 0.00%
Net margin (144.95%) — 0.00%
Free cash flow margin (221.15%) — 0.00%
Return on equity (147.44%) (62.39%) (51.58%)
Return on assets (34.30%) (54.30%) (45.91%)
Return on invested capital 0.00% (324.39%) 0.00%

Growth

Metric EDIT LXEO Biotechnology median
Revenue growth (TTM) 7.42% — 7.20%
EPS growth (last fiscal year) 37.50% 39.81% 29.04%
Revenue growth, 5-year CAGR (14.89%) — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric EDIT LXEO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.82 8.69 4.79
Net debt to EBITDA 0.94 1.67 1.01

Dividend

Metric EDIT LXEO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EDIT LXEO Biotechnology median
Market cap 263.92m 267.43m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack